Pfizer (PFE) says the FDA has set a action date for Hympavzi in Q2 2026

Pfizer's announcement regarding the FDA action date for Hympavzi in Q2 2026 indicates extended timelines for its drug development.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Philip Morris International Inc (PM) Q4 2025 (USD): EPS 1.70 (exp. 1.70), Revenue 10.4bln (exp. 10.38bln), Next FY EPS 9.38-8.53 (exp. 8.34); on track to outperform 2024-2026 growth algorithm

Under Armour Inc. (UAA) Q3 2026 (USD): Adj. EPS 0.09 (exp. -0.02), Revenue 1.33bln (exp. 1.31bln); FY adj. EPS view 0.10-0.11 (exp. 0.05)

Pfizer (PFE) says the FDA has set a action date for Hympavzi in Q2 2026

Indian Foreign Exchange Reserves (Jan/30) 723.77B (Prev. 709.41B)

Tank maker KNDS dismisses investment interest from Rheinmetall (RHM GY), Financial Times report

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

While this sets clear expectations for investors about upcoming milestones, the long lead time may affect sentiment and investment decisions in the stock, particularly in the context of competitive products and market conditions in the pharmaceuticals sector.

Related headlines

The whole workspace, free to try.

Try it free